Notice of Results

RNS Number:8110H
Amarin Corporation Plc
15 November 2007


          AMARIN ANNOUNCES THIRD QUARTER 2007 RESULTS CONFERENCE CALL



LONDON, United Kingdom, November 15, 2007 Amarin Corporation plc (NASDAQ: AMRN)
("Amarin" or "Company") today announced that it will be discussing its third
quarter 2007 results in a conference call at 8.30 a.m. Eastern time/1.30 p.m.
GMT on Tuesday, November 20, 2007. Rick Stewart, Chief Executive Officer, Alan
Cooke, President and Chief Financial Officer and Declan Doogan, Head of Research
and Development can be heard by dialling [phone] (tollfree) in the U.S.
or [phone] (toll) elsewhere. Conference ID 24477922.


The call will also be webcast live and a link will be on the company's website
at www.amarincorp.com. Information on the company's website is not part of this
release.


For those who cannot listen to the live broadcast, a replay will be available
shortly after the conference call in the link on the company's website
www.amarincorp.com or by dialling [phone] (tollfree) in the U.S. or +1
[phone] (toll) elsewhere, and entering access code 24477922.


About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.


Amarin's CNS development pipeline includes two programs in Parkinson's disease,
one in epilepsy and one in memory and cognition. Amarin is initiating a series
of cardiovascular preclinical and clinical programs to capitalize on the known
therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin
also has a proprietary lipid-based technology platform for the targeted
transport of molecules through the liver and/or to the brain that can be
leveraged in a wide range of disease applications for its own product pipeline
or with potential partners.


Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.


For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.






Contacts:

Amarin [phone]

Rick Stewart Chief Executive Officer

Alan Cooke President and Chief Financial Officer

[e-mail]


Investors:

Lippert/Heilshorn & Associates, Inc. [phone]

Anne Marie Fields

Bruce Voss [phone]


Media:

Powerscourt [phone]

Rory Godson

Paul Durman

Sarah Daly


Disclosure Notice:


The information contained in this document is as of November 15, 2007. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not be able to achieve
compliance with the Nasdaq minimum bid price and/or other continued listing
criteria within the required timeframe or at all and the risk that the Company
may not be able to successfully appeal a Nasdaq delisting determination); the
success of Amarin's research and development activities; decisions by regulatory
authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect
the commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in International and US generally
accepted accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the
SEC on March 5 2007, Amarin's statutory annual report for the year ended 31
December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its
Reports of Foreign Issuer on Form 6-K furnished to the SEC.








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NORXELFFDFBFFBZ